143 related articles for article (PubMed ID: 16886606)
1. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression.
Iczkowski KA; Omara-Opyene AL; Shah GV
Anticancer Res; 2006; 26(4B):2863-72. PubMed ID: 16886606
[TBL] [Abstract][Full Text] [Related]
2. Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion.
Iczkowski KA; Omara-Opyene AL; Kulkarni TR; Pansara M; Shah GV
Anticancer Res; 2005; 25(3B):2075-83. PubMed ID: 16158948
[TBL] [Abstract][Full Text] [Related]
3. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
[TBL] [Abstract][Full Text] [Related]
4. Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.
Yang K; Tang Y; Habermehl GK; Iczkowski KA
BMC Cancer; 2010 Jan; 10():16. PubMed ID: 20074368
[TBL] [Abstract][Full Text] [Related]
5. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells.
Robbins EW; Travanty EA; Yang K; Iczkowski KA
BMC Cancer; 2008 Sep; 8():260. PubMed ID: 18793421
[TBL] [Abstract][Full Text] [Related]
6. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing.
Zeng Y; Wodzenski D; Gao D; Shiraishi T; Terada N; Li Y; Vander Griend DJ; Luo J; Kong C; Getzenberg RH; Kulkarni P
Cancer Res; 2013 Jul; 73(13):4123-33. PubMed ID: 23667174
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level.
Iczkowski KA; Bai S; Pantazis CG
Anticancer Res; 2003; 23(4):3129-40. PubMed ID: 12926045
[TBL] [Abstract][Full Text] [Related]
8. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
Afify A; Purnell P; Nguyen L
Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378
[TBL] [Abstract][Full Text] [Related]
9. Cell adhesion molecule CD44: its functional roles in prostate cancer.
Iczkowski KA
Am J Transl Res; 2010 Sep; 3(1):1-7. PubMed ID: 21139802
[TBL] [Abstract][Full Text] [Related]
10. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells.
Welsh CF; Zhu D; Bourguignon LY
J Cell Physiol; 1995 Sep; 164(3):605-12. PubMed ID: 7544357
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
12. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance.
Klingbeil P; Marhaba R; Jung T; Kirmse R; Ludwig T; Zöller M
Mol Cancer Res; 2009 Feb; 7(2):168-79. PubMed ID: 19208744
[TBL] [Abstract][Full Text] [Related]
13. Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.
Miwa T; Nagata T; Kojima H; Sekine S; Okumura T
Int J Oncol; 2017 Sep; 51(3):771-780. PubMed ID: 28677740
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation.
Terpe HJ; Störkel S; Zimmer U; Anquez V; Fischer C; Pantel K; Günthert U
Am J Pathol; 1996 Feb; 148(2):453-63. PubMed ID: 8579108
[TBL] [Abstract][Full Text] [Related]
15. Distinct CD44 splice variants differentially affect collateral artery growth.
Bot PT; Grundmann S; van Royen N; Joosten SP; Schirmer SH; de Kleijn DP; Pals ST; Pasterkamp G; Piek JJ; Hoefer IE
Curr Vasc Pharmacol; 2013 Jan; 11(1):13-20. PubMed ID: 23391418
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin is a prostate epithelium-derived growth stimulatory peptide.
Chien J; Ren Y; Qing Wang Y; Bordelon W; Thompson E; Davis R; Rayford W; Shah G
Mol Cell Endocrinol; 2001 Jul; 181(1-2):69-79. PubMed ID: 11476942
[TBL] [Abstract][Full Text] [Related]
17. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
[TBL] [Abstract][Full Text] [Related]
18. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of expression of cell adhesion molecule (CD44) splice variants: CD44 standard (CD44s) and v5, v6 isoforms in oral leukoplakias: an immunohistochemical study.
Godge PY; Poonja LS
Indian J Dent Res; 2011; 22(3):493-4. PubMed ID: 22048598
[TBL] [Abstract][Full Text] [Related]
20. The CD44 receptor of the mouse LB T-cell lymphoma: analysis of the isoform repertoire and ligand binding properties by reverse-transcriptase polymerase chain reaction and antisense oligonucleotides.
Wallach SB; Friedmann A; Naor D
Cancer Detect Prev; 2000; 24(1):33-45. PubMed ID: 10757121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
